Healthcare Realty Trust (HR) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
5 May, 2026Executive summary
Achieved record leasing activity in Q1 2026, executing over 2 million sq ft and 290 leases, with 93.5% tenant retention and improved lease economics.
Reported GAAP net loss of $0.00 per share, NAREIT FFO of $0.35 per share, and Normalized FFO of $0.41 per share.
Raised full-year 2026 Normalized FFO guidance to $1.59–$1.65 per share and Same Store Cash NOI growth guidance to 3.75%–4.75%.
Completed $125 million in transactions, including an $89 million JV acquisition and $33 million in dispositions.
Repurchased 5.7 million shares for $100 million and secured $400 million in new term loan commitments.
Financial highlights
Q1 2026 revenues were $279.0 million, with property operating expenses of $100.1 million and G&A expenses of $17.3 million.
Normalized FFO totaled $144.4 million ($0.41/share); FAD was $112.9 million (75% payout ratio).
Same Store Cash NOI growth reached 6.9% year-over-year, with occupancy at 92.3%.
Cash leasing spreads averaged 4.2%, with one in four leases above 5%.
Net Debt to Adjusted EBITDA stood at 5.5x; liquidity of $1.2 billion as of March 31, 2026.
Outlook and guidance
Increased full-year Normalized FFO per share guidance by $0.01 to $1.59–$1.65 per share.
Raised Same Store Cash NOI growth guidance by 25 basis points to 3.75%–4.75%.
Guidance excludes impacts from future acquisitions, developments, or share repurchases not already discussed.
Management expects to fund 2026 dividends from operations or other liquidity sources.
Approximately 10-15% of leases are expected to expire annually, with a typical tenant retention rate of 75-90%.
Latest events from Healthcare Realty Trust
- Strong NOI growth, high occupancy, and disciplined capital allocation drive sector leadership.HR
Investor presentation30 Apr 2026 - Director elections, auditor ratification, and say-on-pay headline the 2026 annual meeting.HR
Proxy filing7 Apr 2026 - Board recommends approval of director nominees, auditor, and executive compensation; strong ESG focus.HR
Proxy filing7 Apr 2026 - Strong leasing, $1.2B asset sales, and improved leverage drive positive 2025 and 2026 outlook.HR
Q4 202513 Feb 2026 - Q2 net loss on impairments, but strong leasing, asset sales, and FFO guidance affirmed.HR
Q2 20242 Feb 2026 - Normalized FFO per share rose 1.2% as leasing, asset sales, and share buybacks drove activity.HR
Q3 202417 Jan 2026 - Record leasing, robust FFO growth, and deleveraging highlight 2024 performance.HR
Q4 202429 Dec 2025 - Normalized FFO per share was $0.39 in Q1 2025, with improved net loss and strong leasing.HR
Q1 202527 Dec 2025 - Board recommends approval of all proposals, with strong focus on pay-for-performance and ESG.HR
Proxy Filing1 Dec 2025